RinaldiVBellucciGRomanoA, et al. ADEM after ChAdOx1 nCoV-19 vaccine: A case report. Mult Scler 2021. Epub ahead of print. DOI: 10.1177/13524585211040222.
2.
Di FilippoMCordioliCMalucchiS, et al. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry. Epub ahead of print 18 August 2021. DOI: 10.1136/jnnp-2021-327200.
3.
AchironAMandelMDreyer-AlsterS, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord2021; 14: 1–8.
4.
ManzanoGMcEntireCMartinez-LageM, et al. Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19. Systematic review and meta-synthesis. Neurol Neuroimmunol Neuroinflamm2021; 8(6): e1080.
5.
VogrigAJanesFGigliGL, et al. Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination. Clin Neurol Neurosurg2021; 208: 106839.
6.
LiuXShawRStuartA, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial. Lancet2021; 398: 856–869.
